Trial Summary
What is the purpose of this trial?
The main purpose of this research study is to determine the maximum tolerable dose (MTD) of SX-682 in combination with nivolumab in patients with metastatic pancreatic ductal adenocarcinoma who have completed at least 16 weeks of first line chemotherapy treatment without evidence of disease progression.
Do I need to stop my current medications for this trial?
The trial protocol does not specify if you need to stop your current medications. However, you cannot use other investigational drugs, medications at immunosuppressive doses, or certain botanical preparations within 28 days before starting the study drug. It's best to discuss your current medications with the study team.
What data supports the idea that SX-682 + Nivolumab for Pancreatic Cancer is an effective treatment?
The available research does not provide specific data on the effectiveness of SX-682 + Nivolumab for Pancreatic Cancer. Instead, it focuses on the use of Nivolumab for other types of cancer, such as non-small cell lung cancer and melanoma. In these cases, Nivolumab has shown to improve survival rates and is better tolerated compared to some other treatments. However, without specific data on pancreatic cancer, we cannot conclude its effectiveness for this condition.12345
What safety data exists for SX-682 + Nivolumab in pancreatic cancer treatment?
The safety data for Nivolumab, a PD-1 inhibitor, includes reports of immune-related adverse events (irAEs) such as pancreatitis, colitis, and other immune-related toxicities. These adverse events have been observed in various cancer treatments involving Nivolumab, either alone or in combination with other drugs like ipilimumab. The management of these irAEs often involves corticosteroids or other immunosuppressive treatments like infliximab. However, specific safety data for the combination of SX-682 and Nivolumab in pancreatic cancer is not detailed in the provided research.678910
Is the treatment SX-682 + Nivolumab a promising treatment for pancreatic cancer?
Yes, the treatment SX-682 + Nivolumab is promising for pancreatic cancer because it shows potential in increasing the number of active immune cells that can fight the cancer, and it has been well-tolerated in trials. This suggests it could help improve survival rates, although more research is needed to confirm these benefits.1112131415
Eligibility Criteria
This trial is for adults over 18 with metastatic pancreatic ductal adenocarcinoma who've completed at least 16 weeks of first-line chemo without the cancer getting worse. They must be able to perform daily activities (ECOG status 0 or 1) and not have brain metastases, active pneumonitis, recent major surgery, other cancers in the last three years, or use immunosuppressants. Participants need functioning organs and can't be pregnant or breastfeeding.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Nivolumab (Checkpoint Inhibitor)
- SX-682 (Chemokine Receptor Antagonist)